Literature DB >> 15994925

Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells.

Michelle R Stettner1, Wenquan Wang, L Burton Nabors, Suman Bharara, Daniel C Flynn, J Robert Grammer, G Yancey Gillespie, Candece L Gladson.   

Abstract

Cellular Src activity modulates cell migration, proliferation, and differentiation, and recent reports suggest that individual members of the Src family may play specific roles in these processes. As we have found that Lyn, but not Fyn, activity promotes migration of glioblastoma cells in response to the cooperative signal generated by platelet-derived growth factor receptor beta and integrin alpha(v)beta3, we compared the activity and expression of Lyn and Fyn in glioblastoma (grade IV) tumor biopsy samples with that in anaplastic astrocytoma (grade III) tumors, nonneoplastic brain, and normal autopsy brain samples. Lyn kinase activity was significantly elevated in glioblastoma tumor samples. Notably, the Lyn kinase activity accounted for >90% of pan-Src kinase activity in glioblastoma samples but only approximately 30% of pan-Src kinase activity in the other groups. The levels of phosphorylation of the autophosphorylation site were consistent with significantly higher Lyn activity in glioblastoma tumor tissue than nonneoplastic brain. Although the normalized levels of Lyn protein and the relative levels of Lyn message were significantly higher in glioblastoma samples than nonneoplastic brain, the normalized levels of Lyn protein did not correlate with Lyn activity in the glioblastoma samples. There was no significant difference in the normalized levels of c-Src and Fyn protein and message in the glioblastoma and nonneoplastic brain. Immunostaining revealed that Lyn is located primarily in the glioblastoma cells in the tumor biopsies. These data indicate that Lyn kinase activity is significantly elevated in glioblastoma tumors and suggest that it is the Lyn activity that promotes the malignant phenotype in these tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15994925     DOI: 10.1158/0008-5472.CAN-04-3688

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  54 in total

1.  Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.

Authors:  David A Reardon; James J Vredenburgh; Annick Desjardins; Katherine B Peters; Sith Sathornsumetee; Stevie Threatt; John H Sampson; James E Herndon; April Coan; Frances McSherry; Jeremy N Rich; Roger E McLendon; Steven Zhang; Henry S Friedman
Journal:  J Neurooncol       Date:  2012-03-10       Impact factor: 4.130

2.  The adaptor protein TRIP6 antagonizes Fas-induced apoptosis but promotes its effect on cell migration.

Authors:  Yun-Ju Lai; Victor T G Lin; Ying Zheng; Etty N Benveniste; Fang-Tsyr Lin
Journal:  Mol Cell Biol       Date:  2010-09-27       Impact factor: 4.272

Review 3.  The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas.

Authors:  Florence Lefranc; Robert Kiss
Journal:  Neoplasia       Date:  2008-03       Impact factor: 5.715

4.  The p21-activated kinase, PAK2, is important in the activation of numerous pancreatic acinar cell signaling cascades and in the onset of early pancreatitis events.

Authors:  Bernardo Nuche-Berenguer; Irene Ramos-Álvarez; R T Jensen
Journal:  Biochim Biophys Acta       Date:  2016-02-18

5.  SYK inhibition blocks proliferation and migration of glioma cells and modifies the tumor microenvironment.

Authors:  Gerald Moncayo; Michal Grzmil; Tatiana Smirnova; Pawel Zmarz; Roland M Huber; Debby Hynx; Hubertus Kohler; Yuhua Wang; Hans-Rudolf Hotz; Nancy E Hynes; Georg Keller; Stephan Frank; Adrian Merlo; Brian A Hemmings
Journal:  Neuro Oncol       Date:  2018-04-09       Impact factor: 12.300

6.  Chicken sarcoma to human cancers: a lesson in molecular therapeutics.

Authors:  Om Prakash; Stephen F Bardot; John T Cole
Journal:  Ochsner J       Date:  2007

7.  A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas.

Authors:  Jana Portnow; Behnam Badie; Susan Markel; An Liu; Massimo D'Apuzzo; Paul Frankel; Rahul Jandial; Timothy W Synold
Journal:  Eur J Cancer       Date:  2013-02-04       Impact factor: 9.162

Review 8.  Inflammatory stress and sarcomagenesis: a vicious interplay.

Authors:  Jürgen Radons
Journal:  Cell Stress Chaperones       Date:  2013-08-27       Impact factor: 3.667

9.  Herpes simplex virus requires VP11/12 to induce phosphorylation of the activation loop tyrosine (Y394) of the Src family kinase Lck in T lymphocytes.

Authors:  Melany J Wagner; James R Smiley
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

10.  Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth.

Authors:  Jiyuan Ke; R Lakshman Chelvarajan; Vishal Sindhava; Darrell A Robertson; Lazaros Lekakis; C Darrell Jennings; Subbarao Bondada
Journal:  Mol Cancer       Date:  2009-12-31       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.